[1]丰有吉,沈铿. 妇产科学[M].第2版.北京:人民卫生出版社,2011:328.[2]Bachtiary B, Schindl M, Ptter R, et al. Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer[J]. Clin Cancer Res, 2003, 9 (6):2234 -2240.[3]Maynard MA, Ohh M. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer[J]. Am J Nephrol, 2004,24(1):1-13.[4]Wan X, Shen N, Mendoza A, et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling[J]. Neoplasia , 2006, 8(5):394-401.[5]Scortegagna M, Morris MA, Oktay Y, et al. The HIF family member EPAS1/HIF-2alpha is required for normal hematopoiesis in mice[J]. Blood, 2003, 102(5):1634-1640. [6]Bangoura G, Yang LY, Huang GW, et al. Expression of HIF-2 alpha/EPAS1 in hepatocellular carcinoma[J]. World J Gastroenterol, 2004, 10(4):525-530.[7]Uchida T, Rossignol F, Matthay MA,et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha expression in lung epithelial cells[J]. J Biol Chem, 2004, 279(15):14871-14878.[8]Wei L, Liu X, Hu C. Correlation between expression of HIF-2α and OCT-4 and prognosis of NSCLC[J]. Zhong Nan Da Xue Xue Bao Yi Xue Bao, 2011, 36(9):854-858.[9]Kim WY, Perera S, Zhou B, et al. HIF2 alpha co-operates with RAS to promote lung tumorigenesis in mice[J]. J Clin Invest, 2009, 119(8):2160-2170.[10]Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells[J]. Cancer Cell, 2009, 15(6):501-513.[11]〖JP+4〗Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer[J]. Int J Radiat Oncol Biol Phys, 2002,53(5):1192-1202.[12]Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival[J]. Br J Cancer,2001,85(6):881-890. |